Meloxicam is a new preferential cvclooxygenase-2 (COX-2) inhibitor currently for the treatment of osteoarthritis and rheumatoid arthritis. Its pharmacokinetic profile is characterized by a prolonged and almost complete absorption and the drug is >99.5% bound to plasma proteins. Meloxicam is metabolized to four biologically inactive main metabolites, which are excreted in both urine and faeces. The elimination half-life (fa) of meloxicam is ~20 h. This is reflected in a total plasma clearance (CL) of 0.42 -0.481/h. Steady-state plasma concentrations are achieved within 3-5 days. The pharmacokinetic parameters of meloxicam are linear over the dose range 7.5-30 mg and bioequrvalence has been shown for a number of different formulations. No interactions were observed following the concomitant administration of food, cimetidine, antacid, aspirin, fJ-acetyldigoxin, methotrexate, warfarin or furosemide. Neither hepatic insufficiency nor moderate renal dysfunction have any relevant effects on the pharmacokinetics of meloxicam and dosage adjustments in the elderly are not required.
PATIENTS AND METHODS
The phannacokinetic characteristics of meloxicam have been extensively investigated and complete plasma concentration-time profiles have been obtained from >400 male and female volunteers as well as in a number of special patient groups (hepatic insufficiency, elderly, renal insufficiency). Meloxicam was administered either as an intravenous or intramuscular solution as well as by oral capsule or tablet, or rectally as a suppository. Drug plasma concentrations were quantified by means of specific and validated high performance liquid chromatography assays. Pharmacokinetic parameters were calculated using standard non-compartmental analyses.
PHARMACOKINETIC PROPERTIES Absorption
The absorption of meloxicam has been investigated following administration of intramuscular solutions, oral capsules or tablets, and rectal suppositories. The absolute bioavailability (F) was 89% [3] for oral capsules after a single 30 mg dose. Maximum meloxicam plasma concentrations (Cmax) were achieved after 5-6 h (fmax) when administered after breakfast [4] . The onset of uvuun of meloxicam occurs much earlier than tmax-The Cmax occurred later (/max was doubled) when meloxicam was administered in a fasted state. During chronic therapy for osteoarthritis or rheumatoid arthritis it is generally more common to administer NSAIDs after a meal, thus the tmaxjs value of 5-6 h for meloxicam is probably the clinically more relevant value. Very similar values were found after rectal administration [3] . Absorption after intramuscular injection is faster than after oral administration, with Cmax occurring after 1-1.5 h [5] . Ninety per cent of the Cmax is achieved after 0.87 h [5] .
Mean plasma concentration-time profiles at steady state are shown in Fig. 1 . Multiple concentration peaks are evident in profiles from individual volunteers which indicate a continual absorption for several hours after the Cmax has been attained. Similar observations with other drugs of this class suggest a recirculation of the drug in the gastrointestinal tract [6, 7] . NSAJDs secreted in the intestinal lumen can be sequestered from the intestine by means of repeated administration of cholestyramine [6, 7] . For meloxicam, this results in a 50% increase in apparent clearance [8] . This suggests meloxicam undergoes gastrointestinal recycling and may account for why the drug does not undergo faster elimination. In the case of possible meloxicam overdosage it may be advantageous to administer cholestyramine or charcoal [9] , thereby eliciting a faster elimination of the drug.
The absorption of meloxicam is independent of dose over the range 7.5-30 mg, leading to dose-linear increases in meloxicam plasma concentrations [3] . This enables easy dose titration in those patients requiring higher or lower doses than normal. A summary of typical pharmacokinetic parameters of meloxicam after single and multiple doses is listed in Table I .
Distribution
Most NSAIDs are highly protein bound to albumin [10] ; meloxicam is no exception, being >99% bound [3] . The binding is consistent over the concentration range encountered in clinical practice. This high protein binding results in a restricted volume of distribution (Vd) of 10-15 1 [3] , which is similar to that reported for other NSAIDs [11] . Animal experiments suggest that meloxicam is predominantly distributed to highly perfused (albumin rich) compartments such as the blood, liver, kidney, etc. [12] . The V<j equates approximately with the extracellular space, although meloxicam readily penetrates other tissues. For example, 40-45% of the accompanying steady-state meloxicam plasma concentrations are found in synovial fluid, slightly lower concentrations being observed in the adjacent tissues [13] . Inflamed tissue is characterized by extravasation and probably, decreased pH values, compared with non-inflamed tissue. Such conditions are ideally suited to 'trap' a NSAID from the circulation. Indeed, high concentrations of meloxicam in inflamed tissue have been observed in animal models [14] .
Metabolism
Meloxicam is almost exclusively eliminated by metabolic degradation. The drug undergoes roughly equal renal and faecal elimination, with <0.25% excreted unchanged in urine and 1.6% of the parent compound present in the faeces. The latter may also represent a small amount of unabsorbed drug [15] . Mctabolically, meloxicam undergoes extensive phase I reactions, and no conjugated derivatives have been detected. The main metabolites are formed by oxidation of the methyl group of the thiazolyl moiety; further metabolites result from a cleavage of the thiazine ring system (Fig. 2) . The metabolism of meloxicam is largely mediated through cytochrome P450 2C, most probably on the isoenzyme 2C9. The four main metabolites of meloxicam (AF-UH 1 SE, UH-AC 110 SE, BIBO 8032 and DS-AC 2 SE) have no biological activity [15] .
Elimination
Oral meloxicam has a total clearance of 0.42-0.48 1/h and an elimination half-life (ty,) of ~20 h [3] . Steady-state plasma concentrations are achieved within 3-5 days. In common with most other NSAIDs, a considerable variation between subjects (interindividual coefficient of variation 30%) has been observed.
In comparison with other NSAIDs of the same class, meloxicam has a relatively short elimination half-life of 20 h. This value allows a once-a-day dosage without the need for a slow release formulation. The values for piroxicam are ~53 h [16] and for tenoxicam -65-70 h [17] . Additionally, steady state is achieved within 3-5 days with meloxicam whereas 1-2 weeks is necessary for the other NSAIDs. NSAIDs with a short elimination half-life, such as diclofenac (t>/, 1-2 h [18] ) need a slow release formulation for a once-daily regimen. The performance of slow release formulations may be influenced by the concomitant intake of food. Diclofenac is a well known example for which quite different concentration-time profiles are seen with and without food [19] . Such food effects are more rare with compounds with a longer elimination half-life.
Interactions
The concomitant administration of food as well as other agents is known to affect the absorption, as well as elimination, of NSAIDs. Thus several pharmacokinetifr interaction trials involving meloxicam have been undertaken which demonstrated the lack of clinically relevant interactions with high-fat food [4] , P-acetyldigoxin [20] , methotrexate [21] , cimetidine [22] , antacids [22] , acetylsalicylic acid [22] or furosemide [23] . Recent data also indicate that there is no relevant interaction with warfarin.
Effects of disease states or age on pharmacokinetics
Excretory functions can be altered by increased age and this may result in drug accumulation. This situation has been reported for some other NSAIDs [24] . Patients suffering from osteoarthritis are often elderly, consequently the pharmacokinetics of meloxicam have been evaluated in elderly arthritic patients. Interestingly, there was no difference in pharmacokinetic parameters between young (£55 yr) and elderly (>65 yr) male patients; however, a 50% increase of meloxicam plasma concentrations in elderly female patients (>65 yr) was noted when compared with young female patients (£55 yr) [25] . This finding was confirmed by applying population kinetic approaches to plasma samples from several hundred patients, although the difference was somewhat smaller (33% increase in the elderly female [data on file, Boehringer Ingelhcim]). However, the incidence of adverse events in elderly females was not higher compared with younger females. Thus the increase does not warrant a dose adjustment. Similar findings have been reported for the structurally related NSAID, piroxicam [26] .
The pharmacokinetics of NSAIDs may be affected by hepatic or renal insufficiency. In summary, for meloxicam there was no relevant influence of hepatic insufficiency or mild-to-moderate renal dysfunction on the drug's pharmacokinetics [27, 28] . Renal failure was associated with reduced total meloxicam plasma concentrations. However, an increase in the free fraction compensated for this effect. Free area under the plasma concentration-time curve values were very similar for both renal failure patients and healthy subjects. Free Cmax values tended to be increased in the renal failure patients. As a safety precaution, the lower dose of 7.5 mg is recommended for patients with end-stage renal failure.
